Generic Name and Formulations:
Pegaptanib sodium 0.3mg/prefilled syringe; soln for oph intravitreous inj; preservative-free.
Bausch Health Companies Inc.
Indications for MACUGEN:
Treatment of neovascular (wet) age-related macular degeneration.
Give by intravitreous inj. 0.3mg once every 6 weeks into the eye to be treated.
Ocular or periocular infections.
Monitor for infection during week following inj (endophthalmitis possible). Monitor intraocular pressure and perfusion of optic nerve. Pregnancy (Cat.B). Nursing mothers.
Vascular endothelial growth factor (VEGF) inhibitor.
Anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbances, vitreous floaters, vitreous opacities, blepharitis, conjunctivitis, photopsia, bronchitis, diarrhea, dizziness, headache, nausea, UTI, others.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Smoking Promotes Disease Progression in Multiple Sclerosis
- Situation Framing, Language Can Influence Decision-Making
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- FDA: Opioid Analgesic REMS Expanded to Include Immediate-Release Products